The Effect of SMN Gene Dosage on ALS Risk and Disease Severity.
Moisse M, Zwamborn R, Van Vugt J, van der Spek R, van Rheenen W, Kenna B, van Eijk K, Kenna K, Corcia P, Couratier P, Vourc'h P, Hardiman O, McLaughin R, Gotkine M, Drory V, Ticozzi N, Silani V, de Carvalho M, Mora J, Povedano M, Andersen P, Weber M, Başak N, Chen X, Eberle M, Al-Chalabi A, Shaw C, Openshaw P, Morrison K, Landers J, Glass J, Robberecht W, van Es M, Van den Berg L, Veldink J, Van Damme P, Project MinE Sequencing Consortium. The Effect of SMN Gene Dosage on ALS Risk and Disease Severity. Ann Neurol 2021; 89:686-697.
15.01.2021
The Effect of SMN Gene Dosage on ALS Risk and Disease Severity.
15.01.2021
Ann Neurol 2021; 89:686-697
Moisse Matthieu, Zwamborn Ramona A J, Van Vugt Joke J F A, van der Spek Rick, van Rheenen Wouter, Kenna Brendan, van Eijk Kristel R, Kenna Kevin P, Corcia Philippe, Couratier Philippe, Vourc'h Patrick, Hardiman Orla, McLaughin Russell, Gotkine Marc, Drory Vivian E, Ticozzi Nicola, Silani Vincenzo, de Carvalho Mamede, Mora Jesus S, Povedano Monica, Andersen Peter Munch, Weber Markus, Başak Nazli A, Chen Xiao, Eberle Michael A, Al-Chalabi Ammar, Shaw Christopher E, Openshaw Peter J M, Morrison Karen E, Landers John E, Glass Jonathan D, Robberecht Wim, van Es Michael, Van den Berg Leonard, Veldink Jan H, Van Damme Philip, Project MinE Sequencing Consortium
Weiter
